Safety, tolerability, and pharmacokinetics of ibrexafungerp in healthy Chinese subjects: a randomized, double-blind, placebo-controlled phase 1 trial.

Liu, Xiaoyan; Zhang, Rui; Li, Rong; Wu, Qiong; Pan, Chao; Yu, Xiangqing; Liu, Yuhui; Wang, Benjie; Yu, Shuwen

Liu, Xiaoyan; Zhang, Rui; Li, Rong; Wu, Qiong; Pan, Chao; Yu, Xiangqing; Liu, Yuhui; Wang, Benjie; Yu, Shuwen.

Afiliación

Liu X; Phase 1 clinical Trial Center, Qilu Hospital of Shandong University, Jinan, China.
Zhang R; NMPA Key Laboratory for Clinical Research and Evaluation of Innovative Drugs, Shandong University, Jinan, China.
Li R; Phase 1 clinical Trial Center, Qilu Hospital of Shandong University, Jinan, China.
Wu Q; NMPA Key Laboratory for Clinical Research and Evaluation of Innovative Drugs, Shandong University, Jinan, China.
Pan C; Phase 1 clinical Trial Center, Qilu Hospital of Shandong University, Jinan, China.
Yu X; NMPA Key Laboratory for Clinical Research and Evaluation of Innovative Drugs, Shandong University, Jinan, China.
Liu Y; Jiangsu Hansoh Pharmaceutical Group Co. Ltd., Lianyungang, China.
Wang B; Jiangsu Hansoh Pharmaceutical Group Co. Ltd., Lianyungang, China.
Yu S; Jiangsu Hansoh Pharmaceutical Group Co. Ltd., Lianyungang, China.

Antimicrob Agents Chemother ; 67(12): e0107523, 2023 12 14.

Article en En | MEDLINE | ID: mdl-37971243

Asunto(s)

Triterpenos; Adulto; Humanos; Masculino; Femenino; Área Bajo la Curva; Método Doble Ciego; Voluntarios Sanos; Triterpenos/efectos adversos; Relación Dosis-Respuesta a Droga

Palabras clave

Chinese; HS-10366; fungal infection; ibrexafungerp; pharmacokinetics; phase 1

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Triterpenos Límite: Adult / Female / Humans / Male Idioma: En Revista: Antimicrob Agents Chemother Año: 2023 Tipo del documento: Article País de afiliación: China

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google